New drug targets mysterious chronic itch
NCT ID NCT07074977
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests a drug called nemolizumab in 50 adults with chronic itching that has no known cause. The goal is to see how the drug works in the body and whether it can reduce itching over 16 weeks. Participants receive either nemolizumab or a placebo injection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nemolizumab
- What this could lead to
- If successful, this could point toward a new treatment option for people with chronic itching that has no clear cause.
- What could go wrong
- This is an early Phase 2 study with only 50 participants, so results may not apply to everyone. The drug may not reduce itching significantly, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PRURITUS OF UNKNOWN ORIGIN are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Galderma Investigational (Site # 7131)
NOT_YET_RECRUITINGSpartanburg, South Carolina, 29307, United States
-
Galderma Investigational (Site# 7048)
NOT_YET_RECRUITINGBaltimore, Maryland, 21201, United States
-
Galderma Investigational Site (#7129)
RECRUITINGBowling Green, Kentucky, 42104, United States
-
Galderma Investigational Site (#7130)
RECRUITINGThe Bronx, New York, 10455, United States
-
Galderma Investigational Site (#8212)
RECRUITINGPortland, Oregon, 97210, United States
-
Galderma Investigational Site (#8255)
RECRUITINGPhiladelphia, Pennsylvania, 19103, United States
-
Galderma Investigational Site (#8295)
NOT_YET_RECRUITINGMiami, Florida, 33136, United States
-
Galderma Investigational Site (#8768)
NOT_YET_RECRUITINGTucson, Arizona, 85718, United States
-
Galderma Investigational Site (#9975)
RECRUITINGSacramento, California, 95815, United States
-
Galderma Investigational Site (site# 7054)
RECRUITINGTampa, Florida, 33609, United States
-
Galderma Investigational Site (site# 7075)
RECRUITINGSan Francisco, California, 94115, United States
-
Galderma Investigational Site (site# 7110)
RECRUITINGNew City, New York, 10956, United States
-
Galderma Investigational Site (site# 7111)
RECRUITINGFargo, North Dakota, 58103, United States
-
Galderma Investigational Site (site# 8003)
RECRUITINGWebster, Texas, 77598, United States
-
Galderma Investigational Site (site# 8021)
NOT_YET_RECRUITINGSan Diego, California, 92123, United States
-
Galderma Investigational Site (site# 8045)
NOT_YET_RECRUITINGQuébec, Quebec, G1V 4X7, Canada
-
Galderma Investigational Site (site# 8108)
RECRUITINGLas Vegas, Nevada, 89145, United States
-
Galderma Investigational Site (site# 8130)
RECRUITINGLos Angeles, California, 90045, United States
-
Galderma Investigational Site (site# 8142)
NOT_YET_RECRUITINGIndianapolis, Indiana, 46250, United States
-
Galderma Investigational Site (site# 8521)
NOT_YET_RECRUITINGSaint Joseph, Missouri, 64506, United States
-
Galderma Investigational Site (site# 8608)
NOT_YET_RECRUITINGSanta Monica, California, 90404, United States
-
Galderma Investigational Site (site# 8636)
RECRUITINGFountain Valley, California, 92708, United States
-
Galderma Investigational Site (site# 8725)
RECRUITINGMorgantown, West Virginia, 26505, United States
-
Galderma Investigational Site (site# 8743)
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Galderma Investigational Site (site# 8862)
RECRUITINGFairfax, Virginia, 22031, United States
-
Galderma Investigational Site (site# 8893)
RECRUITINGBirmingham, Alabama, 35244, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.